Skip to main content
Top
Published in: International Journal of Hematology 6/2016

01-12-2016 | Images in Hematology

Chédiak–Higashi-like granules and waxy Auer bodies in a case of acute promyelocytic leukemia

Authors: Daisuke Ogiya, Hiromichi Matsushita, Hiromichi Murayama, Kiyoshi Ando

Published in: International Journal of Hematology | Issue 6/2016

Login to get access

Excerpt

A 31-year-old man presented with pharyngeal pain and purpura on the right dorsal surface of the hand for 1 week. The complete blood count showed leukopenia and thrombocytopenia (white blood cell count, 1.8 × 109/L; platelet count, 51 × 109/L). Coagulation tests revealed the following: prothrombin time–international normalized ratio (PT–INR) of 1.46; fibrinogen level of 36 mg/dL; fibrin degradation products (FDP) level of 50.9 μg/mL; D-dimer level of 60.6 μg/mL; and thrombin–antithrombin III (TAT) complex level of 54.6 ng/mL. These results indicated disseminated intravascular coagulopathy (DIC). A bone marrow examination revealed hypocellularity with 77 % abnormal promyelocytes. Promyelocytes were variable in size, and contained round, ovoid, distorted, or folded nuclei, as well as rich cytoplasm with abundant azurophilic granules. Chédiak–Higashi-like granules were frequently observed in these promyelocytes (Fig. 1a). Auer bodies were often thick, and some were waxy (Fig. 1b). A diagnosis of acute promyelocytic leukemia (APL) was made on the detection of the t(15;17) (q22;q21) translocation and the resultant PML/RARA fusion transcript. FLT3–ITD mutation was negative.
Metadata
Title
Chédiak–Higashi-like granules and waxy Auer bodies in a case of acute promyelocytic leukemia
Authors
Daisuke Ogiya
Hiromichi Matsushita
Hiromichi Murayama
Kiyoshi Ando
Publication date
01-12-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2078-z

Other articles of this Issue 6/2016

International Journal of Hematology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine